SubsidieMeestersSystemic delivery of oncolytic herpes simplex viruses retargeted to cancer-specific receptors. Virus optimization and business planning.
This project aims to enhance systemic delivery of innovative oncolytic herpesviruses targeting HER2-positive tumors, facilitating clinical trials and commercialization to improve metastatic cancer treatment.
Projectdetails
Introduction
Solid tumors, in particular metastatic ones, represent unmet clinical needs and are the second leading cause of death worldwide. Oncolytic viruses (OVs) kill tumors while sparing normal cells. They are a distinct class of novel anti-cancer agents, frequently administered by intratumoral injection.
Systemic Delivery of OVs
A Holy Grail in the innovation of OVs is the possibility to administer them systemically, e.g., through intravenous injection, allowing OVs to search for and scavenge metastases within the human body. The systemic delivery of OVs addresses societal challenges by meeting the needs of metastatic patients, who are those most affected by cancer and in need of innovative therapies.
Innovative Oncolytic Herpesviruses
The Principal Investigator has generated a family of innovative oncolytic herpesviruses (ReHVs) that specifically target HER2-positive tumors (HER2-ReHVs). In preclinical studies, HER2-ReHVs exhibit:
- High specificity for HER2-positive cancers.
- High anti-tumor efficacy against metastatic tumors.
- Vaccination against metastatic-like tumors.
- High safety profiles.
These properties position ReHVs well for systemic delivery. The ReHV technology is protected by a portfolio of patents.
Objectives of the Proposal
The objectives of this Proposal are twofold:
- To improve the systemic delivery of ReHVs by identifying the obstacles that constrain such administration and developing novel strategies to overcome them. This includes high-risk, high-gain modifications that make ReHVs better suited for systemic delivery.
- To carry out initiatives for technological transfer, which involves the development and commercialization of ReHVs. This includes:
- Detailed planning of activities to take ReHVs to authorization for First-in-Human clinical experimentation.
- Development of a business plan.
- Conducting OV market analysis and searching for investors.
By combining the development and commercialization initiatives with technological advancements, this POC is expected to achieve the broader objective of progressing ReHVs into clinical experimentation and ultimately bringing them to patients.
Financiële details & Tijdlijn
Financiële details
| Subsidiebedrag | € 150.000 |
| Totale projectbegroting | € 150.000 |
Tijdlijn
| Startdatum | 1-5-2022 |
| Einddatum | 31-10-2023 |
| Subsidiejaar | 2022 |
Partners & Locaties
Projectpartners
- FONDAZIONE POLICLINICO SANT'ORSOLA ONLUSpenvoerder
- ALMA MATER STUDIORUM - UNIVERSITA DI BOLOGNA
Land(en)
Vergelijkbare projecten binnen European Research Council
| Project | Regeling | Bedrag | Jaar | Actie |
|---|---|---|---|---|
Targeting the undruggable: Leveraging neomorphic DNA-binding preferences of chimeric fusion oncogenes to promote cancer suicideThis project aims to develop a novel viral vector strategy that leverages oncogenic transcription factors to selectively induce cancer cell suicide in aggressive tumors like Ewing sarcoma. | ERC Consolid... | € 1.992.235 | 2024 | Details |
Synergistic Antitumor Activity of Microbiome and OMV-based in situ VaccinationThe project aims to enhance immunotherapy by combining intratumoral injection of engineered bacterial OMVs with oral Bifidobacterium to boost anti-tumor immunity and improve treatment efficacy. | ERC Proof of... | € 150.000 | 2023 | Details |
Development of an immune-armed therapeutic adenoviral platform for pediatric brain tumorsThe POPCORN project aims to develop an innovative oncolytic virus platform that enhances anti-tumor immune responses for treating aggressive pediatric brain tumors, improving survival rates and quality of life. | ERC Proof of... | € 150.000 | 2025 | Details |
A combined diagnostic and targeted gene therapy platform for brain tumor relapseThis project aims to develop a novel gene therapy using engineered viruses to target therapy-resistant brain tumor cells, improving patient prognosis and treatment outcomes. | ERC Proof of... | € 150.000 | 2022 | Details |
Maximizing the use of a first clinically viable MYC inhibitorThis project aims to enhance the therapeutic potential of the MYC inhibitor Omomyc by exploring its delivery methods and combination therapies for treating brain tumors and understanding MYC biology. | ERC Advanced... | € 2.499.904 | 2024 | Details |
Targeting the undruggable: Leveraging neomorphic DNA-binding preferences of chimeric fusion oncogenes to promote cancer suicide
This project aims to develop a novel viral vector strategy that leverages oncogenic transcription factors to selectively induce cancer cell suicide in aggressive tumors like Ewing sarcoma.
Synergistic Antitumor Activity of Microbiome and OMV-based in situ Vaccination
The project aims to enhance immunotherapy by combining intratumoral injection of engineered bacterial OMVs with oral Bifidobacterium to boost anti-tumor immunity and improve treatment efficacy.
Development of an immune-armed therapeutic adenoviral platform for pediatric brain tumors
The POPCORN project aims to develop an innovative oncolytic virus platform that enhances anti-tumor immune responses for treating aggressive pediatric brain tumors, improving survival rates and quality of life.
A combined diagnostic and targeted gene therapy platform for brain tumor relapse
This project aims to develop a novel gene therapy using engineered viruses to target therapy-resistant brain tumor cells, improving patient prognosis and treatment outcomes.
Maximizing the use of a first clinically viable MYC inhibitor
This project aims to enhance the therapeutic potential of the MYC inhibitor Omomyc by exploring its delivery methods and combination therapies for treating brain tumors and understanding MYC biology.
Vergelijkbare projecten uit andere regelingen
| Project | Regeling | Bedrag | Jaar | Actie |
|---|---|---|---|---|
Development of a cell immunotherapy targeting non-conventional tumor antigens in ovarian cancerErVaccine aims to develop TCR-OV1, a novel TCR-T cell therapy targeting cancer-specific antigens to improve early detection and treatment outcomes for ovarian cancer patients. | EIC Accelerator | € 2.499.999 | 2024 | Details |
IntraVenous Immune BoostHEPHAISTOS-Pharma's ONCO-Boost is a groundbreaking intravenous TLR4 immunostimulant aimed at treating metastatic cancers, potentially curing 10x more patients than current therapies. | EIC Accelerator | € 2.499.999 | 2024 | Details |
Macrophage-based immunotherapy of platinum-resistant ovarian cancerThe MACOV project aims to develop a groundbreaking macrophage-based therapy for platinum-resistant ovarian cancer, preparing it for Phase I clinical trials through comprehensive pre-clinical efficacy and safety studies. | EIC Transition | € 2.499.998 | 2022 | Details |
Targeting Cancer with ERV VaccinesInProTher is developing BreakImmune, an immunotherapy targeting HERVs to create a cancer vaccine (IPT001) that enhances immune responses against solid tumors. | EIC Accelerator | € 2.500.000 | 2022 | Details |
Functional chemical reprogramming of cancer cells to induce antitumor immunityThe RESYNC consortium aims to revolutionize cancer immunotherapy by reprogramming cancer cells into antigen-presenting dendritic cells using small molecules for personalized and safer treatments. | EIC Pathfinder | € 2.966.695 | 2024 | Details |
Development of a cell immunotherapy targeting non-conventional tumor antigens in ovarian cancer
ErVaccine aims to develop TCR-OV1, a novel TCR-T cell therapy targeting cancer-specific antigens to improve early detection and treatment outcomes for ovarian cancer patients.
IntraVenous Immune Boost
HEPHAISTOS-Pharma's ONCO-Boost is a groundbreaking intravenous TLR4 immunostimulant aimed at treating metastatic cancers, potentially curing 10x more patients than current therapies.
Macrophage-based immunotherapy of platinum-resistant ovarian cancer
The MACOV project aims to develop a groundbreaking macrophage-based therapy for platinum-resistant ovarian cancer, preparing it for Phase I clinical trials through comprehensive pre-clinical efficacy and safety studies.
Targeting Cancer with ERV Vaccines
InProTher is developing BreakImmune, an immunotherapy targeting HERVs to create a cancer vaccine (IPT001) that enhances immune responses against solid tumors.
Functional chemical reprogramming of cancer cells to induce antitumor immunity
The RESYNC consortium aims to revolutionize cancer immunotherapy by reprogramming cancer cells into antigen-presenting dendritic cells using small molecules for personalized and safer treatments.